DUPIXENT® (dupilumab) for Moderate-to-Severe Eczema that is …
DUPIXENT® (dupilumab) is a subcutaneous injectable prescription medicine for uncontrolled moderate-to-severe eczema (atopic dermatitis) in adults & children aged 6 months & older. Serious side effects can occur.
DUPIXENT® (dupilumab) for Moderate-to-Severe Atopic Dermatitis …
DUPIXENT® (dupilumab) is indicated for the treatment of patients aged 6 mo. & older with uncontrolled moderate-to-severe atopic dermatitis. Serious adverse reactions may occur. Please see Important Safety Information and full PI on website.
Dupilumab - StatPearls - NCBI Bookshelf
2024年2月28日 · Dupilumab is an injectable prescription medication administered subcutaneously to treat severe and refractory forms of atopic dermatitis. The US Food and Drug Administration (FDA) approved the medication in April 2017 to treat moderate-to-severe, resistant, atopic dermatitis unresponsive to conventional therapy, including topical corticosteroids.
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
2016年12月15日 · In two phase 3 trials of identical design involving patients with atopic dermatitis, dupilumab improved the signs and symptoms of atopic dermatitis, including pruritus, symptoms of anxiety and...
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis ...
2014年7月10日 · To address the importance of Th2-related biologic factors in atopic dermatitis, we evaluated dupilumab in four randomized, double-blind, placebo-controlled trials involving adults with...
Efficacy and safety of dupilumab in adults with moderate-to …
2016年1月2日 · Interpretation: Dupilumab improved clinical responses in adults with moderate-to-severe atopic dermatitis in a dose-dependent manner, without significant safety concerns. Our findings show that IL-4 and IL-13 are key drivers of atopic dermatitis. Funding: Sanofi and Regeneron Pharmaceuticals. Copyright © 2016 Elsevier Ltd. All rights reserved.
Dupilumab in Adults With Moderate to Severe Atopic Dermatitis
Findings In this open-label extension study of 2677 adults with moderate to severe atopic dermatitis, dupilumab was well tolerated with no new safety incidents and showed sustained efficacy (including improvements in atopic dermatitis …
Dupilumab in Adults With Moderate to Severe Atopic Dermatitis
In this open-label extension study of 2677 adults with moderate to severe atopic dermatitis, dupilumab was well tolerated with no new safety incidents and showed sustained efficacy (including improvements in atopic dermatitis signs, symptoms, and quality of life) for up to 5 years.
Dupilumab for Atopic Dermatitis: The Silver Bullet We Have Been ...
Dupilumab has been recently approved for the management of atopic dermatitis. It is a human monoclonal antibody that inhibits the binding of key interleukins involved in the pathogenesis of atopic dermatitis, thus blocking the signaling mechanisms and disrupting the disease progression.
Practical Management of Patients with Atopic Dermatitis on Dupilumab
Dupilumab is approved to treat moderate-to-severe atopic dermatitis (AD) in several countries in patients as young as 6 years of age. Since its approval, practical issues related to the use of dupilumab for AD have arisen, with particular interest ...